{"product_id":"xgn-ansoff-analysis","title":"(XGN) Exagen Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock the Full Ansoff Matrix for Deeper Strategic Insight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Exagen Inc. Ansoff Matrix Analysis maps the company’s growth options across market penetration, market development, product development, and diversification in a concise, actionable format—ideal for strategy, investing, or presentations. This page contains a real preview of the analysis so you can evaluate style and substance before buying; purchase the full version to unlock the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpand AVISE CTD use in symptomatic connective tissue disease workups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAVISE CTD is Exagen Inc.'s flagship blood test for symptomatic patients with possible connective tissue disease, so the market-penetration play is to drive deeper use inside existing U.S. rheumatology practices where diagnosis is still hard and slow.\u003c\/p\u003e\n\u003cp\u003eThat is a current-market share move, not a new-product bet, and it fits the large, recurring test pool in lupus and overlap workups.\u003c\/p\u003e\n\u003cp\u003eExagen reported $53.1 million in full-year 2024 revenue and 32,000+ test volumes in a recent quarter, showing room to grow AVISE CTD use per clinic.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIncrease repeat use of AVISE Lupus and AVISE SLE Monitor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAVISE Lupus uses B-cell C4d and erythrocyte-bound C4d, while AVISE SLE Monitor supports ongoing SLE management, so both can be ordered again as care continues. That makes the play a deeper push into Exagen Inc.'s existing lupus base, raising tests per patient over time. In a chronic disease with recurring follow-ups, repeat use can lift revenue without needing new patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrow AVISE APS utilization in antiphospholipid syndrome evaluation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExagen Inc. can grow AVISE APS use by making it a standard add-on in autoimmune workups, so more clinicians choose it for antiphospholipid syndrome evaluation. APS is tied to recurrent thrombosis and pregnancy loss, and earlier, broader testing can lift pull-through on an established panel. That supports market penetration without needing a new product launch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDrive AVISE Anti-CarP and AVISE PC4d adoption in rheumatoid arthritis care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eExagen can push AVISE Anti-CarP and AVISE PC4d deeper into existing rheumatology accounts by tying both tests to RA risk stratification. AVISE Anti-CarP helps flag patients at risk for severe disease, while AVISE PC4d measures platelet-bound C4d, so the pitch is higher test frequency and a wider product mix in the same customer base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus on current rheumatology accounts\u003c\/li\u003e\n\u003cli\u003eUse AVISE Anti-CarP for severe RA risk\u003c\/li\u003e\n\u003cli\u003eUse AVISE PC4d for immune activity data\u003c\/li\u003e\n\u003cli\u003eGrow testing frequency and mix\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIncrease AVISE HCQ and AVISE MTX monitoring in treated patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eExagen Inc. can deepen penetration by pushing repeat use of AVISE HCQ, which tracks hydroxychloroquine levels, and AVISE MTX, a patented, validated blood test, in patients already seen by rheumatologists. Because these tests are therapy-monitoring tools, they can be ordered again and again in current markets, lifting follow-on revenue without new disease areas. Exagen reported 2024 revenue of about $52 million, so even modest repeat-test growth can matter.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRepeat testing drives follow-on revenue.\u003c\/li\u003e\n\u003cli\u003eRheumatology channels already exist.\u003c\/li\u003e\n\u003cli\u003eAVISE MTX is patented and validated.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExagen Growth Hinges on More Repeat AVISE Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMarket penetration for Exagen Inc. is about selling AVISE tests harder inside the same rheumatology base, not entering new diseases. The clearest lever is repeat and add-on use across CTD, lupus, APS, RA risk, and therapy monitoring.\u003c\/p\u003e\n\u003cp\u003eExagen Inc. reported $53.1 million in FY2024 revenue and 32,000+ tests in a recent quarter, so higher tests per clinic can still move sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$53.1M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecent quarter volume\u003c\/td\u003e\n\u003ctd\u003e32,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey lever\u003c\/td\u003e\n\u003ctd\u003eRepeat testing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes Exagen Inc.’s growth strategy across existing and new products and markets\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Exagen Inc. Ansoff Matrix for quick, structured growth strategy decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eConsolidates primary, reputable sources to validate Exagen's Ansoff growth paths, enabling fast verification and defensible, traceable strategy decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpand AVISE testing beyond core rheumatology into related specialty referrals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExagen Inc. can use AVISE across more U.S. physicians who manage autoimmune disease, not just core rheumatology. AVISE already fits SLE, RA, APS, and vasculitis, so referrals can extend into nephrology, dermatology, neurology, and hematology. With lupus affecting about 1.5 million Americans and RA about 1.3 million, this is market development using the same menu.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroaden use of AVISE APS in thrombosis and pregnancy-risk care pathways\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExagen Inc. can broaden AVISE APS into thrombosis and pregnancy-risk care, since APS testing helps diagnose and manage antiphospholipid syndrome, a disorder linked to clotting and recurrent pregnancy loss. In the U.S., APS affects about 50 per 100,000 people, and VTE impacts nearly 900,000 Americans each year, widening the clinician pool. The assay stays unchanged; only the customer segment expands.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntroduce AVISE SLE Prognostic into wider co-management settings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAVISE SLE Prognostic moves Exagen Inc. beyond rheumatology by screening 3 major SLE complication risks: kidney, brain, and cardiovascular. That fits market development because it uses one existing test in wider co-management settings, where earlier risk stratification can support shared care between rheumatology, nephrology, neurology, and cardiology.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUse AVISE Vasculitis AAV in broader ANCA-associated vasculitis pathways\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAVISE Vasculitis AAV can move from a niche test into broader ANCA-associated vasculitis referral paths, giving Exagen Inc. a clear new-market use for an existing product. It helps assess and monitor patients across rheumatology, nephrology, and other specialty settings where vasculitis is managed. That matters because ANCA-associated vasculitis is rare but high-acuity, so tests that support faster routing can win share in more centers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExtends one test into more referral pathways\u003c\/li\u003e\n\u003cli\u003eFits assessment and monitoring use cases\u003c\/li\u003e\n\u003cli\u003eTargets specialty care networks, not just one clinic\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eExtend AVISE brand coverage across additional U.S. practice geographies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eExagen can grow AVISE by adding more rheumatology and autoimmune care centers across the U.S. without changing the test menu. The move fits market development: the same AVISE portfolio reaches new regional accounts, so sales can expand on footprint, not product change.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame AVISE set, wider U.S. reach\u003c\/li\u003e\n\u003cli\u003eTarget more rheumatology centers\u003c\/li\u003e\n\u003cli\u003eScale with geography, not redesign\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis is the cleanest lever when a Company already sells nationwide but still has white space in local referral networks and specialty practices.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExagen Expands AVISE Into New Specialty Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExagen Inc.’s market development leans on AVISE in wider specialty channels, not a new product. The best near-term paths are rheumatology-adjacent referrals in nephrology, neurology, dermatology, and hematology, where lupus affects about 1.5 million Americans and RA about 1.3 million.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUse\u003c\/th\u003e\n\u003cth\u003eNew buyer\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAVISE SLE\u003c\/td\u003e\n\u003ctd\u003eNephrology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAVISE APS\u003c\/td\u003e\n\u003ctd\u003eOB\/GYN\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eExagen Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis preview reflects the real Ansoff Matrix analysis document you'll receive—professional, structured, and ready to use. The full, editable version is unlocked after purchase and contains the complete strategic options, risk notes, and recommended actions for Exagen Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvance AVISE SLE Monitor as a dedicated longitudinal management tool\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExagen Inc. can advance AVISE SLE Monitor, already a biomarker blood test, into a dedicated longitudinal tool for serial SLE follow-up. That adds more value for current rheumatology accounts and deepens menu breadth without needing a new customer base.\u003c\/p\u003e\n\u003cp\u003eThe move fits product development: build more utility around ongoing disease tracking, treatment response, and flare monitoring. For Exagen Inc., that can improve test frequency and customer stickiness across its installed rheumatology network.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScale AVISE HCQ for therapeutic drug monitoring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAVISE HCQ is a product-development move because it adds hydroxychloroquine monitoring to Exagen Inc.'s autoimmune testing menu, helping clinicians manage lupus and related care more closely. Therapeutic drug monitoring can improve dose checks and adherence, so it deepens use in the same market instead of chasing new ones. That gives Exagen Inc. a specialized, higher-value option with clear fit inside existing rheumatology workflows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScale AVISE MTX for methotrexate monitoring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eScale AVISE MTX for methotrexate monitoring within Exagen Inc.’s current rheumatology base. AVISE MTX is a patented, validated blood test that helps manage autoimmune patients on methotrexate by tracking treatment response and supporting dose decisions.\u003c\/p\u003e\n\u003cp\u003eThis is a product development move in the Ansoff Matrix: Exagen Inc. deepens testing depth with existing customers rather than entering a new market. The fit is strong where rheumatology clinics already use Exagen Inc. tests and can add AVISE MTX to ongoing care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eStrengthen AVISE Vasculitis AAV as an analyte-based panel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAVISE Vasculitis AAV fits Exagen Inc.’s product development play, because it keeps the company in the same autoimmune diagnostics market while adding a more granular analyte-based panel. By using individual analytes to help physicians assess and monitor disease, it shows steady refinement of disease-specific testing rather than a move into a new market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame market, deeper panel\u003c\/li\u003e\n\u003cli\u003eIndividual analytes support monitoring\u003c\/li\u003e\n\u003cli\u003eRefines disease-specific testing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDevelop novel patented biomarkers through the AHN Research Institute collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eExagen Inc.'s research collaboration and license agreement with AHN Research Institute supports product development by advancing novel patented biomarkers, which is the clearest pipeline add-on in the company profile. In Exagen Inc.'s latest reported results, product development still matters because new biomarker assets can lift assay utility and keep the menu differentiated. The AHN tie-up is a focused, lower-capital path to new IP.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAHN Research Institute: biomarker pipeline support\u003c\/li\u003e\n\u003cli\u003eLicense plus collaboration model\u003c\/li\u003e\n\u003cli\u003eClosest fit: product development\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExagen Deepens Autoimmune Testing With New Monitoring Tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExagen Inc.’s product development in the Ansoff Matrix means adding more autoimmune testing utility for the same rheumatology customers. AVISE SLE Monitor, AVISE HCQ, AVISE MTX, and AVISE Vasculitis AAV all deepen follow-up, dosing, and disease monitoring.\u003c\/p\u003e\n\u003cp\u003eThe AHN Research Institute collaboration also fits this play by adding novel biomarker IP without leaving Exagen Inc.’s core market.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003eFit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAVISE HCQ\u003c\/td\u003e\n\u003ctd\u003eTherapy monitoring\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAVISE MTX\u003c\/td\u003e\n\u003ctd\u003eDose tracking\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAHN tie-up\u003c\/td\u003e\n\u003ctd\u003eNew biomarkers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialize next-generation biomarker products from AHN-led research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe AHN Research Institute tie-up can push Exagen beyond its AVISE menu and into new biomarker-based tests, which is classic diversification. If even 1 or 2 biomarkers turn into reimbursable clinical offerings, Exagen adds a new revenue stream instead of just selling more of the same assays.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnter additional autoimmune indications with new biomarker assays\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFor Exagen Inc., diversification means adding biomarker assays for autoimmune diseases beyond its core SLE, RA, APS, and vasculitis focus, pairing new products with new disease markets. This is the highest-risk Ansoff move, but it can widen the addressable market and reduce reliance on a narrow test menu. The key is proving clinical utility fast so payers and labs adopt each new assay.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuild new diagnostic categories beyond CTD and lupus testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExagen Inc. can use AVISE’s autoimmune base to move into new diagnostic categories beyond CTD and lupus, which would open fresh customer groups and reduce reliance on one disease cluster. This is true diversification, not just a test-line extension. \u003c\/p\u003e\n\u003cp\u003eThe logic is strong if new panels target high-need areas with unmet clinical demand, because broader menu depth can raise test adoption and recurring lab revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMove from single-disease panels to broader precision medicine solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eExagen Inc. already sells biomarker and autoantibody tests for autoimmune care, so diversification would mean moving from one-disease panels to broader precision medicine tools that cover more patient needs and testing paths.\u003c\/p\u003e\n\u003cp\u003eThis step can expand use cases in rheumatology, where the company can bundle diagnostics, risk signals, and treatment guidance into a fuller decision tool instead of a narrow lab test. That matters because autoimmune disease affects about 50 million Americans, and broader precision testing can win more of that workflow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMoves beyond AVISE-style single-use panels\u003c\/li\u003e\n\u003cli\u003eTargets wider autoimmune care needs\u003c\/li\u003e\n\u003cli\u003eCreates a fuller precision diagnostics offer\u003c\/li\u003e\n\u003cli\u003eCan deepen share of the rheumatology workflow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUse patented biomarker licensing to enter adjacent testing markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eExagen already has patented biomarker tech and a biomarker license, so it can push into adjacent test panels without starting from zero. That makes diversification cheaper and faster than building a new assay stack in-house. In practice, licensing new biomarker assets can turn one platform into several revenue lines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUses existing patent moat\u003c\/li\u003e\n\u003cli\u003eFaster entry into adjacent diagnostics\u003c\/li\u003e\n\u003cli\u003eCreates new product revenue streams\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExagen’s Risky Diversification Bet: New Biomarker Tests, New Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExagen Inc.’s diversification means moving beyond AVISE autoimmune panels into new biomarker tests and new disease areas, such as broader precision diagnostics. That is a higher-risk Ansoff step, but it can add fresh revenue streams if each assay proves clinical utility and payer value.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eKey point\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore focus\u003c\/td\u003e\n\u003ctd\u003eAutoimmune diagnostics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiversification path\u003c\/td\u003e\n\u003ctd\u003eNew biomarker assays\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue driver\u003c\/td\u003e\n\u003ctd\u003eNew reimbursable tests\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235142115593,"sku":"xgn-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/xgn-ansoff-matrix.webp?v=1785736483","url":"https:\/\/dcfanalyst.com\/products\/xgn-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}